Contrary to its role in MM, our studies demonstrate that FBXO9 expression is consistently decreased across AML subtypes and that reduction of its E3 ligase activity promotes the progression of AML and tends to decrease survival time, both in mouse studies and patient cohorts. This evidence concerns the gene FBXO9 and Miyoshi myopathy.